



- *Dr Jennifer Schneider appointed CEO, Dr Helen Bright joins as VP of R&D, and Professor David Roblin as Chair of the Board of Directors*
- *Appointments to help drive continued development of Centauri's antimicrobial resistance research to identify novel therapeutic candidates using the Alphamer platform*

London, UK, 23 June 2022: Centauri Therapeutics Limited (Centauri), an immunotherapy company focused on the treatment of infectious diseases, today announced three senior appointments: Dr Jennifer Schneider as Chief Executive Officer (CEO), Dr Helen Bright as Vice President (VP) of R&D, and Professor David Roblin FRCP FMedSci as Chair of the Board of Directors. The appointments will help to support the continued development of Centauri's antimicrobial resistance (AMR) research projects to identify and advance novel antibacterial candidates through to first-in-human trials, using the Alphamer® platform.

Dr Jennifer Schneider joins Centauri as CEO with 20 years' experience working with life science companies, universities, and non-governmental organisations, globally, to deliver expert guidance on antibiotic policy, partnering, and fundraising. Dr Schneider was most recently Executive Officer, North America for the Global Antibiotic Research & Development Partnership (GARDP). She received her PhD in Molecular Biology from the University of Notre Dame, and a Master of Public Health in Epidemiology and International Health from the University of Michigan.

Dr Helen Bright joins as VP of R&D from Medicines Discovery Catapult, where she supported the discovery and development of anti-infectives, vaccines, and diagnostics as Head of Infection Biology. She has over 30 years' experience focused on infectious diseases within the biopharmaceutical industry, with senior scientific and operational leadership roles at AstraZeneca, Pfizer, and GlaxoSmithKline, advancing novel therapeutic candidates through the clinic to commercialisation. Dr Bright holds a PhD in Virology and Immunology from Newcastle upon Tyne University.

Professor David Roblin, Chair of the Board of Directors, currently CEO of Relation Therapeutics, brings an extensive track record in academic research, therapeutic development, product commercialisation, and fundraising. After five years' medical practice in university hospitals, Professor Roblin held senior leadership positions for over 20 years at Bayer and Pfizer, where he oversaw the successful development of several infectious disease therapeutics, including azithromycin, ciprofloxacin, and moxifloxacin. He is Chair of Scientific Translation at the Francis Crick Institute, Professor of Translational Medicine at St George's Hospital, and an honorary Professor of Medicine at Swansea University.

Dr Jennifer Schneider, CEO, Centauri Therapeutics, said: *"The Alphamer platform is a transformative approach that harnesses a patient's pre-existing antibodies to induce a pathogen-directed immune response to target bacterial infections effectively. This technology has enormous potential in the global fight against AMR, and I am delighted to be joining the senior team as CEO, alongside Dr Bright and Professor Roblin, as we work to progress novel antibacterial candidates to the clinic."*

The new appointments join Centauri's esteemed Dr Mike Westby, Chief Scientific Officer (CSO), and Pamela Brown, Head of Chemistry, to further strengthen the senior leadership team.

Dr Mike Westby, CSO, Centauri Therapeutics, commented: *"We are delighted to welcome all three members to our senior leadership team following our recent Series A close. Between them they bring an impressive wealth of experience across infectious disease research, drug development and product commercialisation. We are proud to attract such high-calibre talent, and have no doubt that Dr*

Schneider, Dr Bright, and Professor Roblin will be invaluable in driving our AMR research projects through to first-in-human trials.”

For more information, please visit <http://www.centauritherapeutics.com>

ENDS

Notes to Editors



*Dr Jennifer Schneider,
CEO,
Centauri
Therapeutics*



*Dr Helen Bright,
VP and Head of R&D,
Centauri Therapeutics*



*Prof David Roblin,
Chair of Board of
Directors, Centauri
Therapeutics*



*Dr Mike Westby,
CSO, Centauri
Therapeutics*

For high resolution images please contact Zyme Communications.

Media contact

Dr Michelle Ricketts
Zyme Communications
Tel: +44 (0) 7789 053 885
Email: michelle.ricketts@zymecommunications.com

Centauri Therapeutics

Dr Jennifer Schneider
CEO
Email: info@centauritherapeutics.com

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please [click here](#).

About Centauri Therapeutics www.centauritherapeutics.com

Centauri Therapeutics is an immunotherapy company focused on infectious diseases. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases. Centauri holds an exclusive worldwide license to exploit the Alphamer immunotherapeutics platform within the field of infectious diseases.

Follow Centauri on LinkedIn [@Centauri Therapeutics Limited](#).